Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Shuta Ohara"'
Autor:
Shota Fukuda, Kenichi Suda, Akira Hamada, Hana Oiki, Shuta Ohara, Masaoki Ito, Junichi Soh, Tetsuya Mitsudomi, Yasuhiro Tsutani
Publikováno v:
Biomedicines, Vol 12, Iss 7, p 1412 (2024)
The emergence of acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) is almost inevitable even after a remarkable clinical response. Secondary mutations such as T790M and C797S are responsible for the resistance to 1st/2nd-generation (1/2G)
Externí odkaz:
https://doaj.org/article/13cb6c41316240a794f6123d8ca258da
Autor:
Takamasa Koga, MD, PhD, Junichi Soh, MD, PhD, Akira Hamada, MD, PhD, Yuki Miyano, MS, Toshio Fujino, MD, PhD, Keiko Obata, Shuta Ohara, MD, PhD, Masaya Nishino, MD, PhD, Masato Chiba, MD, PhD, Masaki Shimoji, MD, PhD, Toshiki Takemoto, MD, PhD, Kenichi Suda, MD, PhD, Kazuko Sakai, MD, PhD, Hidenori Sato, PhD, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100554- (2023)
Introduction: Lung tumor organoids (LTOs) have attracted attention as in vitro preclinical models; however, their clinical and experimental applications have not been fully established. Methods: We attempted to establish LTOs from resected specimens
Externí odkaz:
https://doaj.org/article/e9026793576d4c6aace4c65a0c8269ab
Autor:
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-14 (2022)
Abstract Background Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/te
Externí odkaz:
https://doaj.org/article/91f7932bd36f4d28ab9a6bce380f3ecc
Autor:
Masaya Nishino, Kenichi Suda, Takamasa Koga, Shuta Ohara, Toshio Fujino, Junichi Soh, Vijaya Tirunagaru, Avanish Vellanki, Robert C. Doebele, Tetsuya Mitsudomi
Publikováno v:
Thoracic Cancer, Vol 12, Iss 10, Pp 1511-1516 (2021)
Abstract Background Approximately 10% of non‐small cell lung cancers (NSCLCs) that harbor epidermal growth factor receptor (EGFR) gene mutations have in‐frame insertions in exon 20 of the EGFR gene. These tumors do not usually respond to currentl
Externí odkaz:
https://doaj.org/article/113f3c44e4bf4bd88a1b39cc70faedeb
Autor:
Akira Hamada, MD, Kenichi Suda, MD, PhD, Toshio Fujino, MD, PhD, Masaya Nishino, MD, PhD, Shuta Ohara, MD, PhD, Takamasa Koga, MD, PhD, Takanobu Kabasawa, MD, PhD, Masato Chiba, MD, PhD, Masaki Shimoji, MD, PhD, Makoto Endoh, MD, PhD, Toshiki Takemoto, MD, PhD, Junichi Soh, MD, PhD, Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100321- (2022)
Introduction: Recent studies have suggested that including presence or absence of ground-glass opacity (GGO) may improve the tumor descriptor (T descriptor) classification in clinical stage I NSCLC. In this study, we analyzed prognostic implications
Externí odkaz:
https://doaj.org/article/e3038b81b06d4260b05a610326300a03
Publikováno v:
Human Pathology: Case Reports, Vol 23, Iss , Pp 200481- (2021)
Type 3 NETs are reported to metastasize to other organs or lymph nodes; however, there are few reports of gastric NETs causing isolated pulmonary metastasis. We report a rare case of primary gastric neuroendocrine tumors (NETs) with lung metastasis.
Externí odkaz:
https://doaj.org/article/97f3e749ca2942ee8505393c3ab80c88
Autor:
Shuta Ohara, Kenji Tomizawa, Shigeki Shimizu, Kenichi Suda, Toshio Fujino, Akira Hamada, Takamasa Koga, Masaya Nishino, Yoshihisa Kobayashi, Katsuaki Sato, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-4 (2019)
Abstract Background A total of 75% of patients with Sjögren’s syndrome are complicated with pulmonary lesions, of which 12% are lymphoma and 6% are amyloid nodules; the coexistence of both is considered to be rare. Case presentation A 67-year-old
Externí odkaz:
https://doaj.org/article/5a843bab51b7499ab8dcdf89c1b00bd6
Publikováno v:
Cells, Vol 10, Iss 2, p 354 (2021)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are first-line drugs for lung cancers with activating EGFR mutations. Although first- and second-generation EGFR-TKIs were standard first-line treatments, acquired resistance (
Externí odkaz:
https://doaj.org/article/a5f9a0e89ddd45508e0c9c3a22fb0b6f
Autor:
Masaya Nishino, Kenichi Suda, Junichi Soh, Akira Hamada, Toshio Fujino, Avanish Vellanki, Tetsuya Mitsudomi, Shuta Ohara, Takamasa Koga, Robert C. Doebele, Vijaya G. Tirunagaru
Publikováno v:
Translational Lung Cancer Research. 10:3659-3670
Background HER2 (ERBB2) activating mutations are present in 2-3% of lung adenocarcinomas; however, no targeted therapy is approved for HER2-altered lung cancers. A novel pan-HER inhibitor, tarloxotinib, is designed to release the active form (tarloxo
Autor:
Akira Hamada, Toshio Fujino, Masaki Shimoji, Junichi Soh, Masato Chiba, Kenichi Suda, Takamasa Koga, Shuta Ohara, Kenji Tomizawa, Toshiki Takemoto, Tetsuya Mitsudomi, Masaya Nishino
Publikováno v:
Surgery Today. 51:1480-1487
Few studies have so far focused on the preoperative presence of venous thromboembolism (VTE) in lung cancer patients undergoing surgery. In this study, we investigated the prevalence and risk factors for preoperative deep venous thrombosis (DVT) in p